𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

✍ Scribed by Florian van Bömmel; Bernhard Zöllner; Christoph Sarrazin; Ulrich Spengler; Dietrich Hüppe; Bernd Möller; Heinz-Hubert Feucht; Bertram Wiedenmann; Thomas Berg

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
590 KB
Volume
44
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mutations associated with lamivudine-res
Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients
✍ S. Gloria Selabe; Azwidowi Lukhwareni; Ernest Song; Yeegan G.M. Leeuw; Rosemary 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract This was an exploratory study to investigate lamivudine‐resistant hepatitis B virus (HBV) strains in selected lamivudine‐naïve HBV carriers with and without human immunodeficiency virus (HIV) co‐infection in South African patients. Thirty‐five lamivudine‐naïve HBV infected patients with

Southern hybridisation analysis of HBV D
Southern hybridisation analysis of HBV DNA in peripheral blood leucocytes and of different cell types: Changes during the natural history and with interferon-α therapy in patients with hepatitis B virus infection
✍ A. P. Catterall; I. M. Murray-Lyon; A. J. Zuckerman; Dr. T. J. Harrison 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 878 KB

## Abstract Hepatitis B virus (HBV) DNA was evaluated in peripheral blood mononuclear cells (PBMC) from 50 individuals utilising Southern hybridisation analysis. HBV DNA sequences were detected in PBMC from 16/29 (55 percent) of chronic hepatitis B virus (HBV) carriers with serum HBeAg and HBV DNA,

Lamivudine therapy in patients undergoin
Lamivudine therapy in patients undergoing liver transplantation for hepatitis b virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immu
✍ McCaughan, Geoffrey W. ;Spencer, Jenean ;Koorey, David ;Bowden, Scott ;Bartholom 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 75 KB 👁 1 views

Recurrent hepatitis B virus (HBV) infection remains a major cause of morbidity and mortality after liver transplantation. Recently, antiviral therapy, such as lamivudine, has become available for prophylaxis against HBV reactivation posttransplantation and for the treatment of HBV recurrent disease.